Published in J Clin Microbiol on December 01, 1993
Genotype profile of human polyomavirus JC excreted in urine of immunocompetent individuals. J Clin Microbiol (1996) 1.41
Latency and reactivation of JC virus in peripheral blood of human immunodeficiency virus type 1-infected patients. J Clin Microbiol (1997) 1.14
Diagnostic value of detecting JC virus DNA in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy. J Clin Microbiol (1995) 1.13
Analysis of PCR as a tool for detection of JC virus DNA in cerebrospinal fluid for diagnosis of progressive multifocal leukoencephalopathy. J Clin Microbiol (1996) 1.06
Cidofovir in combination with HAART and survival in AIDS-associated progressive multifocal leukoencephalopathy. J Neurol (2008) 0.80
New commercially available PCR and microplate hybridization assay for detection and differentiation of human polyomaviruses JC and BK in cerebrospinal fluid, serum, and urine samples. J Clin Microbiol (2006) 0.79
Improved detection of JC virus DNA in cerebrospinal fluid for diagnosis of AIDS-related progressive multifocal leukoencephalopathy. J Clin Microbiol (1996) 0.78
Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet (1971) 11.92
PARTICLES RESEMBLING PAPOVA VIRUSES IN HUMAN CEREBRAL DEMYELINATING DISEASE. Science (1965) 3.32
Detection of BK virus and JC virus in urine and brain tissue by the polymerase chain reaction. J Clin Microbiol (1989) 2.94
Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. A review of the literature with a report of sixteen cases. Ann Intern Med (1987) 2.79
Detection of JC virus DNA in peripheral lymphocytes from patients with and without progressive multifocal leukoencephalopathy. Ann Neurol (1992) 2.07
Distribution of nonintegrated DNA from JC papovavirus in organs of patients with progressive multifocal leukoencephalopathy. J Infect Dis (1983) 1.44
Analysis of JC virus DNA purified directly from human progressive multifocal leukoencephalopathy brains. J Virol (1981) 1.36
Genetic characterization of JC virus Tokyo-1 strain, a variant oncogenic in rodents. Virus Res (1987) 1.27
AIDS-associated progressive multifocal leukoencephalopathy (PML): comparison to non-AIDS PML with in situ hybridization and immunohistochemistry. Neurology (1990) 1.00
Progressive multifocal leukoencephalopathy in patients with HIV infection: lack of impact of early diagnosis by stereotactic brain biopsy. J Acquir Immune Defic Syndr (1992) 0.98
Amplification of JC virus DNA from brain and cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy. Neurology (1991) 0.98
Progressive multifocal leukoencephalopathy in persons infected with human immunodeficiency virus, San Francisco, 1981-1989. Ann Neurol (1991) 0.98
Use of a molecular probe for detecting JCV DNA directly in human brain material. J Med Virol (1986) 0.97
Detection of JC virus DNA by polymerase chain reaction in patients with progressive multifocal leukoencephalopathy. J Infect Dis (1990) 0.94
A double-label method detects both early (T-antigen) and late (capsid) proteins of JC virus in progressive multifocal leukoencephalopathy brain tissue from AIDS and non-AIDS patients. J Neuroimmunol (1988) 0.84
Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science (1997) 10.35
Isolation of a new human retrovirus from West African patients with AIDS. Science (1986) 7.97
Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet (2003) 7.94
Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology (1999) 5.55
Herpesvirus-like DNA sequences in patients with Mediterranean Kaposi's sarcoma. Lancet (1995) 3.81
Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet (1998) 3.45
Mycobacterium simiae and Mycobacterium avium-M. intracellulare mixed infection in acquired immune deficiency syndrome. J Clin Microbiol (1987) 3.01
Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy. Nat Med (1998) 2.99
Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood (2001) 2.37
Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology (1999) 2.36
Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Med (2003) 2.30
Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology (2001) 2.29
HIV-1/HIV-2 seronegativity in HIV-1 subtype O infected patients. Lancet (1994) 2.25
Sporadic Creutzfeldt-Jakob disease mimicking nonconvulsive status epilepticus. Neurology (2010) 2.17
Several groups among human herpesvirus 6 strains can be distinguished by Southern blotting and polymerase chain reaction. J Clin Microbiol (1991) 2.16
AIDS across Europe, 1994-98: the EuroSIDA study. Lancet (2000) 2.13
HIV-1 infection in an individual homozygous for CCR5 delta 32. Seroco Study Group. Lancet (1997) 2.11
Hepatitis C virus and essential mixed cryoglobulinaemia. Br J Rheumatol (1993) 2.08
[Management of pregnant women infected with HIV at Bichat Hospital between 1990 and 1998: analysis of 202 pregnancies]. Gynecol Obstet Fertil (2001) 2.05
[Mode of delivery of HIV-infected women: a retrospective study of 358 pregnancies followed in the same hospital between 2000 and 2004]. Gynecol Obstet Fertil (2006) 2.03
Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood (2001) 1.98
Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group. Int J Epidemiol (1997) 1.97
Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Gut (2000) 1.94
High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis (2009) 1.89
The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology (2001) 1.87
Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects. Neurology (2004) 1.82
Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS (2001) 1.81
Cellular and plasma viral load in patients infected with HIV-2. AIDS (1993) 1.76
HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. AIDS (1999) 1.75
Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy. Br J Cancer (2006) 1.73
T cell receptor gamma/delta+ lymphocyte subsets during HIV infection. Clin Exp Immunol (1989) 1.72
Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. J Med Virol (2001) 1.68
The level of human immunodeficiency virus (HIV) type 1 RNA in cerebrospinal fluid as a marker of HIV encephalitis. Clin Infect Dis (1998) 1.67
CD4+Ki67+ lymphocytes in HIV-infected patients are effector T cells accumulated in the G1 phase of the cell cycle. Eur J Immunol (2000) 1.62
HIV-1-associated cognitive/motor complex: absence of neuronal loss in the cerebral neocortex. Neurology (1993) 1.56
European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med (2008) 1.54
Identification of crystals in kidneys of AIDS patients treated with foscarnet. Am J Kidney Dis (1998) 1.50
Variations in tumour oxygen tension (pO2) during accelerated radiotherapy of head and neck carcinoma. Eur J Cancer (1998) 1.49
Lymphadenopathy-associated virus type 2 in AIDS and AIDS-related complex. Clinical and virological features in four patients. Lancet (1987) 1.49
Hepatitis virus infections in heart transplant recipients: epidemiology, natural history, characteristics, and impact on survival. Gastroenterology (2000) 1.47
HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother (2008) 1.47
Pyogenic bacterial pneumonia in human immunodeficiency virus-infected inpatients: a clinical, radiological, microbiological, and epidemiological study. Clin Infect Dis (1998) 1.44
Response to interferon alpha treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus. Gut (1999) 1.44
Sporadic CJD clinically mimicking variant CJD with bilateral increased signal in the pulvinar. Neurology (2002) 1.43
Dynamics of viral variants in HIV-1 Nef and specific cytotoxic T lymphocytes in vivo. J Immunol (1996) 1.43
Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. J Infect Dis (1995) 1.43
Variability of human immunodeficiency virus type 2 (hiv-2) infecting patients living in france. Virology (2001) 1.40
Non-organ specific autoantibodies associated with chronic C virus hepatitis. J Hepatol (1993) 1.39
Dynamics of HIV-specific CD8+ T lymphocytes with changes in viral load.The RESTIM and COMET Study Groups. J Immunol (2000) 1.39
A life-threatening adverse reaction during trimethoprim-sulfamethoxazole desensitization in a previously hypersensitive patient infected with human immunodeficiency virus. Clin Infect Dis (1996) 1.39
HFRS after a wild rodent bite in the Haute-Savoie--and risk of exposure to Hantaan-like virus in a Paris laboratory. Lancet (1984) 1.38
Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology (1998) 1.37
Foscarnet nephrotoxicity: mechanism, incidence and prevention. Am J Nephrol (1989) 1.35
Herpes-like DNA sequences, AIDS-related tumors, and Castleman's disease. N Engl J Med (1995) 1.34
Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses (2005) 1.34
HIV-1 sensitivity to zidovudine: a consensus culture technique validated by genotypic analysis of the reverse transcriptase. J Virol Methods (1992) 1.34
Pentamidine and pancreatitis. Ann Intern Med (1986) 1.34
Liver/kidney microsome antibody type 1 and hepatitis C virus infection. Hepatology (1992) 1.32
Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet (2001) 1.32
Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study. J Antimicrob Chemother (2011) 1.32
Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study. Ann Intern Med (1999) 1.30
Impact of discrepancies between the Abbott realtime and cobas TaqMan assays for quantification of human immunodeficiency virus type 1 group M non-B subtypes. J Clin Microbiol (2009) 1.30
HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy. AIDS (2000) 1.29
Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors. J Clin Microbiol (2005) 1.29
Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology (1991) 1.28
Serum immunoglobulin G subclass dysbalances in the lymphadenopathy syndrome and acquired immune deficiency syndrome. Clin Exp Immunol (1986) 1.28
HIV-2 infection in two homosexual men in France. Lancet (1987) 1.27
Vitamin C preferential toxicity for malignant melanoma cells. Nature (1980) 1.26
Acute hepatitis C in HIV-infected men who have sex with men. HIV Med (2004) 1.26
Susceptibility of HIV-1 isolates to zidovudine: correlation between widely applicable culture test and PCR analysis. J Acquir Immune Defic Syndr (1992) 1.25
Antibody patterns to herpesviruses in Kaposi's sarcoma. II. Serological association of American Kaposi's sarcoma with cytomegalovirus. Int J Cancer (1978) 1.25
A one-year virological survey of acute intussusception in childhood. J Med Virol (1982) 1.24
Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure. AIDS (2001) 1.24
Isolation of an unusual Mycobacterium species from an AIDS patient with acute lymphadenitis. J Clin Microbiol (2000) 1.24
Distribution of radiation sensitivities for human tumor cells of specific histological types: comparison of in vitro to in vivo data. Int J Radiat Oncol Biol Phys (1986) 1.24
Diagnosis of toxoplasmosis in patients with AIDS by isolation of the parasite from the blood. N Engl J Med (1991) 1.23
CD4+CD7-CD57+ T cells: a new T-lymphocyte subset expanded during human immunodeficiency virus infection. Blood (1992) 1.23
Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients. Lancet (1995) 1.22
Effects of zidovudine in 365 consecutive patients with AIDS or AIDS-related complex. Lancet (1988) 1.21
Epidemiology of cryptosporidiosis among European AIDS patients. Genitourin Med (1996) 1.20
Quantification of proviral load of human immunodeficiency virus type 2 subtypes A and B using real-time PCR. J Clin Microbiol (2001) 1.19
Maternal virus load during pregnancy and mother-to-child transmission of human immunodeficiency virus type 1: the French perinatal cohort studies. SEROGEST Cohort Group. J Infect Dis (1997) 1.17
Evaluation of the use of dried spots and of different storage conditions of plasma for HIV-1 RNA quantification. HIV Med (2007) 1.17
Prevalence of human herpesvirus 8 infection measured by antibodies to a latent nuclear antigen in patients with various dermatologic diseases. Arch Dermatol (1998) 1.17
Comparative evaluation of hepatitis C virus RNA quantitation by branched DNA, NASBA, and monitor assays. Hepatology (1999) 1.17
Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. HIV Med (2007) 1.17